These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39082898)

  • 1. Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data.
    Chen H; Hashizume K; Kanefendt F; Brase C; Schmitz S; Liu T
    Clin Transl Sci; 2024 Aug; 17(8):e13895. PubMed ID: 39082898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, an Oral Small Molecule Factor XIa Inhibitor, in Healthy Chinese Volunteers.
    Xu J; Zhao N; Huang J; Li J; Zhao X; Xiang Q; Yang S; Dong Y; Wang H; Li Y; Yang G; Cui Y
    Clin Drug Investig; 2023 Jun; 43(6):435-445. PubMed ID: 37326942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.
    Kubitza D; Heckmann M; Distler J; Koechel A; Schwers S; Kanefendt F
    Br J Clin Pharmacol; 2022 Jul; 88(7):3447-3462. PubMed ID: 35014061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers.
    Liu T; Hashizume K; Krieg E; Chen H; Mukaida Y; Thelen K; Friedrichs F; Willmann S; Schwers S; Solms A; Yu R
    Clin Transl Sci; 2024 Apr; 17(4):e13784. PubMed ID: 38563414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants.
    Li X; Haranaka M; Li H; Liu P; Chen H; Klein S; Reif S; Francke K; Friedrich C; Okumura K
    Clin Pharmacokinet; 2024 Jun; 63(6):901-915. PubMed ID: 38907175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
    Rao SV; Kirsch B; Bhatt DL; Budaj A; Coppolecchia R; Eikelboom J; James SK; Jones WS; Merkely B; Keller L; Hermanides RS; Campo G; Ferreiro JL; Shibasaki T; Mundl H; Alexander JH;
    Circulation; 2022 Oct; 146(16):1196-1206. PubMed ID: 36030390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.
    Perera V; Luettgen JM; Wang Z; Frost CE; Yones C; Russo C; Lee J; Zhao Y; LaCreta FP; Ma X; Knabb RM; Seiffert D; DeSouza M; Mugnier P; Cirincione B; Ueno T; Frost RJA
    Br J Clin Pharmacol; 2018 May; 84(5):876-887. PubMed ID: 29346838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
    Piccini JP; Caso V; Connolly SJ; Fox KAA; Oldgren J; Jones WS; Gorog DA; Durdil V; Viethen T; Neumann C; Mundl H; Patel MR;
    Lancet; 2022 Apr; 399(10333):1383-1390. PubMed ID: 35385695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa.
    Thomas D; Kanefendt F; Schwers S; Unger S; Yassen A; Boxnick S
    J Thromb Haemost; 2021 Oct; 19(10):2407-2416. PubMed ID: 34192419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
    Kadokura T; Kashiwa M; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
    Biopharm Drug Dispos; 2013 Nov; 34(8):431-41. PubMed ID: 23929659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.
    Nowotny B; Thomas D; Schwers S; Wiegmann S; Prange W; Yassen A; Boxnick S
    J Thromb Haemost; 2022 Jul; 20(7):1684-1695. PubMed ID: 35490404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.
    Shoamanesh A; Mundl H; Smith EE; Masjuan J; Milanov I; Hirano T; Agafina A; Campbell B; Caso V; Mas JL; Dong Q; Turcani P; Christensen H; Ferro JM; Veltkamp R; Mikulik R; De Marchis GM; Robinson T; Lemmens R; Stepien A; Greisenegger S; Roine R; Csiba L; Khatri P; Coutinho J; Lindgren AG; Demchuk AM; Colorado P; Kirsch B; Neumann C; Heenan L; Xu L; Connolly SJ; Hart RG;
    Lancet; 2022 Sep; 400(10357):997-1007. PubMed ID: 36063821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
    Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single and multiple postprandial dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban in healthy Chinese volunteers
.
    Chen X; Liu D; Wu Y; Liu Y; Song H; Jiang J; Hu P
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):256-263. PubMed ID: 28025966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers.
    Mendell J; Tachibana M; Shi M; Kunitada S
    J Clin Pharmacol; 2011 May; 51(5):687-94. PubMed ID: 20534818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose-escalation phase I study.
    Zhang JY; Ruan ZR; Jiang B; Yang DD; Wang JY; Hu Y; Wang YR; Wang YM; Lin YF; Wang LL; Lou HG
    Clin Transl Sci; 2024 Apr; 17(4):e13787. PubMed ID: 38558535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
    Shibata M; Hatta T; Saito M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
    Clin Drug Investig; 2020 May; 40(5):469-484. PubMed ID: 32274653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.
    Perera V; Wang Z; Luettgen J; Li D; DeSouza M; Cerra M; Seiffert D
    Clin Transl Sci; 2022 Feb; 15(2):330-342. PubMed ID: 34558200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study.
    Wang Z; Zhao X; He P; Chen S; Jiang J; Harada A; Brooks S; Cui Y
    Adv Ther; 2020 Sep; 37(9):3916-3928. PubMed ID: 32691242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects.
    Jiang J; Hu Y; Zhang J; Yang J; Mueck W; Kubitza D; Bauer RJ; Meng L; Hu P
    Thromb Haemost; 2010 Jan; 103(1):234-41. PubMed ID: 20062915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.